GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mind Medicine Inc (FRA:MMQ) » Definitions » Buyback Yield %

Mind Medicine (FRA:MMQ) Buyback Yield % : -34.07 (As of Jun. 24, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Mind Medicine Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Mind Medicine's current buyback yield was -34.07%.


Mind Medicine Buyback Yield % Historical Data

The historical data trend for Mind Medicine's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mind Medicine Buyback Yield % Chart

Mind Medicine Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Buyback Yield %
-7.51 -13.44 -50.79 -4.96

Mind Medicine Quarterly Data
Sep19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.09 -3.77 -9.55 -6.82 -106.31

Competitive Comparison of Mind Medicine's Buyback Yield %

For the Biotechnology subindustry, Mind Medicine's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mind Medicine's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mind Medicine's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Mind Medicine's Buyback Yield % falls into.



Mind Medicine Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Mind Medicine's Buyback Yield for the fiscal year that ended in Dec. 2023 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 6.904) / 139.0867992
=-4.96%

Mind Medicine's annualized Buyback Yield for the quarter that ended in Mar. 2024 is calculated as

Buyback Yield=Net Issuance of Stock(Annualized) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) * Annualized Factor / Market Cap
=- (0 + 161.905) * 4 / 609.161272
=-106.31%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the annualized quarterly data, the Repurchase of Stock and Issuance of Stock data used here is four times the quarterly (Mar. 2024) data.


Mind Medicine Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Mind Medicine's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Mind Medicine (FRA:MMQ) Business Description

Traded in Other Exchanges
Address
One World Trade Center, Suite 8500, New York, NY, USA, 10007
Mind Medicine Inc is a psychedelic medicine biotech company that discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The firm is having an approach towards developing the next generation of psychedelic inspired medicines and therapies.

Mind Medicine (FRA:MMQ) Headlines

No Headlines